ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,572.85
0.10%
US Tech 100
19,965.20
0.36%
Dow Jones
39,344.79
-0.08%
Brent Oil
84.985
-0.50%
Bitcoin
57,589.50
1.56%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Personalis Inc (PSNL) Quote

Personalis Inc

Personalis Inc (PSNL)

Persimmon PLC
Persimmon PLC
Persimmon PLC
1.51
-0.02
(-1.31%)
Closed July 08 4:00PM
Delayed by 15 minutes
1.46
-0.05
( -3.31% )
Pre Market: 4:32AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.46
Bid
1.46
Ask
1.48
Volume
382
0.00 Day's Range 0.00
0.8906 52 Week Range 2.43
Market Cap
78.428M
Previous Close
1.51
Open
-
Last Trade
2
@
1.48
Last Trade Time
05:01:37
Financial Volume
-
VWAP
-
Average Volume (3m)
265,291
Shares Outstanding
51,938,839
Dividend Yield
-
PE Ratio
-0.72
Earnings Per Share (EPS)
-2.09
Revenue
73.48M
Net Profit
-108.3M

About Personalis Inc

Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT... Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.personalis.com
Headquarters
Dover, Delaware, USA
Founded
1970
Personalis Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker PSNL. The last closing price for Personalis was $1.51. Over the last year, Personalis shares have traded in a share price range of $ 0.8906 to $ 2.43.

Personalis currently has 51,938,839 shares outstanding. The market capitalization of Personalis is $78.43 million. Personalis has a price to earnings ratio (PE ratio) of -0.72.

PSNL Latest News

More News

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3rd Annual Tools / Dx...

June 18 2024
Business Wire

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, June 21, 2024 at 8:00 a.m...

June 13 2024
Business Wire

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

Personalis will host a webinar call on June 19th, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time to present ASCO highlights from the conference Personalis, Inc. (Nasdaq: PSNL) announced...

June 04 2024
Business Wire

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’...

May 31 2024
Business Wire

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT...

May 22 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

May 21 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

May 21 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 21 2024
Edgar (US Regulatory)

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a...

May 17 2024
Business Wire

Personalis Reports First Quarter 2024 Financial Results

Raises full year revenue guidance due to greater pharma testing demand Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for...

May 08 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2823.72881355931.181.751.178441651.5029156CS
40.1511.45038167941.311.751.1353536331.38800877CS
120.22518.21862348181.2351.851.1352652911.41432439CS
26-0.68-31.77570093462.142.311.123260141.47599152CS
52-0.56-27.72277227722.022.430.89063645401.48293194CS
156-21.47-93.632795464522.9324.10.89064176385.79932199CS
260-21.49-93.638344226622.9553.460.890648004314.26062949CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PEGYPineapple Energy Inc
$ 2.21
(84.17%)
5.77M
ZAPPZapp Electric Vehicles Group Ltd
$ 13.21
(42.97%)
1.14M
SVMHSRIVARU Holding Ltd
$ 0.2232
(17.47%)
1.62M
ZPTAZapata Computing Holdings Inc
$ 0.6691
(16.63%)
780k
BTCSBTCS Inc
$ 1.63
(16.43%)
73
INDVIndivior PLC
$ 8.76
(-42.89%)
35.53k
SHPWShapeways Holdings Inc
$ 0.38
(-22.07%)
148.63k
TXMDTherapeuticsMD Inc
$ 1.38
(-18.84%)
24
GNLNGreenlane Holdings Inc
$ 0.2406
(-16.80%)
1.36M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.59965
(-15.83%)
46.38k
PEGYPineapple Energy Inc
$ 2.21
(84.17%)
5.77M
MYNZMainz BioMed NV
$ 0.5516
(15.64%)
4.63M
MAXNMaxeon Solar Technologies Ltd
$ 0.2712
(0.44%)
3.91M
SVMHSRIVARU Holding Ltd
$ 0.2232
(17.47%)
1.62M
GNLNGreenlane Holdings Inc
$ 0.2406
(-16.80%)
1.36M

PSNL Discussion

View Posts
glenn1919 glenn1919 2 months ago
PSNL............................https://stockcharts.com/h-sc/ui?s=PSNL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
PSNL..................................https://stockcharts.com/h-sc/ui?s=PSNL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 months ago
PSNL new 52=week low
👍️0
ottoman ottoman 9 months ago
Damn, is Cathy dumping? This turd sandwich never taste any better the more I nibble.
👍️0
Monksdream Monksdream 9 months ago
PSNL new 52 week low
👍️0
Invest-in-America Invest-in-America 2 years ago
PSNL: Got some nice REVS/INCOME news late yesterday, Peeps --- could get a little run-up today.
https://pulse2.com/why-the-personalis-stock-increased-over-10-psnl/
👍️0
Timetravelerdos Timetravelerdos 4 years ago
Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis has been contracted by the VA MVP since 2012, the program has accelerated and over 50,000 of these genomes have been delivered in 2020.

"The VA MVP is the largest whole genome sequencing project in the United States and this is a significant milestone for both the program and for Personalis," said John West, Chief Executive Officer. "Population-scale sequencing projects of this nature represent a cornerstone in our effort to accelerate the advancement of precision medicine across a wide range of disease areas. With our sizable investments in the technology and infrastructure, necessary to win and execute these projects, Personalis sees population genomics and health as key priorities for our company. We congratulate the VA MVP for their visionary leadership and note that VA scientists now list over 50 peer reviewed publications from the Program."

https://finance.yahoo.com/news/personalis-announces-delivery-100-000th-210700535.html
👍️0
JGrumby JGrumby 5 years ago
Hearing that Monday PSNL will start to get Wall street research reports. Look at PSNL vs GH and NVTA etc
👍️0
JGrumby JGrumby 5 years ago
Nice day after the post IPO sell off.
👍️0

Your Recent History

NASDAQ
PSNL
Personalis
BIT
I08671
Intesa Sanpaolo
BIT
I07031
INTESA SANPAOLO
BIT
I08357
Intesa Sanpaolo
BIT
UB03T1
UniCredit Bank
BIT
S31941
Societe Generale Effekten
BIT
I07887
Intesa Sanpaolo
BIT
P1YAQ7
NLBNPIT1YAQ7 20991231 46...
COIN
ESTOGBP
BIT
UC6W17
Unicredit Bank
AQSE
COTN.GB
WisdomTree Commodity Sec...
BIT
UC16ZE
Unicredit Bank
BIT
F12744
Vontobel Financial Produ...
BIT
S32140
Societe Generale Effekten
BIT
P20W12
NLBNPIT20W12 20240920 48
LSE
AAU
Ariana Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved